TransMedics Group Q1 2025 Update: OCS Transplant Revenue Detailed
Ticker: TMDX · Form: 10-Q · Filed: May 8, 2025 · CIK: 1756262
| Field | Detail |
|---|---|
| Company | Transmedics Group, Inc. (TMDX) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, revenue, credit-agreement
TL;DR
TransMedics Q1 2025 10-Q shows OCS transplant revenue for Liver & Lung, plus credit agreement details. #TransplantTech
AI Summary
TransMedics Group, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates, including revenue from its Organ Care System (OCS) Transplant products, specifically the Liver and Lung products. The company also reported on stock-based compensation expenses and the status of its credit agreements, including a Term Loan with Canadian Imperial Bank of Commerce.
Why It Matters
This filing provides investors with a quarterly update on TransMedics' financial health and the performance of its key organ transplant technology, impacting its valuation and future growth prospects.
Risk Assessment
Risk Level: medium — The company's reliance on specific product lines and credit facilities introduces financial and operational risks.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial data is reported.)
- 2024-01-01 to 2024-03-31 — Q1 2024 Period (Represents the comparative period for financial results.)
- 2025-01-01 to 2025-03-31 — Q1 2025 Period (Represents the current fiscal quarter for financial results.)
Key Players & Entities
- TransMedics Group, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 200 MINUTEMAN ROAD (address) — Company's business and mailing address
- ANDOVER (location) — City of company's address
- MA (location) — State of company's address
- 01810 (zip_code) — Zip code of company's address
- 9785520900 (phone_number) — Company's business phone number
- tmdx:OcsTransplantRevenueMember (financial_metric) — Revenue from Organ Care System Transplant
- tmdx:LiverProductMember (product) — Specific OCS transplant product
- tmdx:LungProductMember (product) — Specific OCS transplant product
FAQ
What was the reported revenue for TransMedics' Organ Care System (OCS) Transplant products in Q1 2025?
The filing indicates revenue for OCS Transplant products, specifically mentioning Liver and Lung products for the period of January 1, 2025, to March 31, 2025.
What is the company's primary business address?
The company's business address is 200 MINUTEMAN ROAD, ANDOVER, MA 01810.
Does the filing mention any specific credit agreements or loans?
Yes, the filing references a Credit Agreement and a Term Loan with Canadian Imperial Bank of Commerce, relevant for the period of January 1, 2025, to March 31, 2025.
What type of financial instruments are mentioned in relation to funding capped call transactions?
The filing mentions Convertible Senior Notes used to fund capped call transactions, with a specific date of May 11, 2023.
What is the Standard Industrial Classification (SIC) code for TransMedics Group, Inc.?
The SIC code for TransMedics Group, Inc. is 3845, which corresponds to ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding TransMedics Group, Inc. (TMDX).